Physicians' Academy for Cardiovascular Education
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.
In this e-learning program, three experts discuss outcomes of relevant trials and guidelines that provide evidence and recommendations for using SGLT2i to improve outcomes in patients with CKD.
What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video. With question to test your knowledge.
Slides as educational service to PACE members and meeting participants.
Slides as educational service to PACE members and meeting participants.
Slides as educational service to PACE members and meeting participants.
Janaka Karalliedde gives an overview of trials and guidelines that provide evidence for using SGLT2 inhibitors to improve outcomes in patients with CKD.
